Mayo Foundation for Medical Education and Research

Council of Scientific and Industrial Research

Dartmouth College

Darmouth College

Debabrata Mukhopadhyay

Mark R Spaller

Priyabrata Mukherjee

Arabinda Chaudhuri

Prathama Satyendra Mainkar

Rajkumar Banerjee

Togapur Pavan Kumar

Srivari Chandrasekhar

Boggavarapu Subrahmanya Sastry

Jerald Mahesh Kumar

Katragadda Suresh Babu

Ummanni Ramesh

Karre Nagaraju

Kanchanapally Tejaswini

Vijay Sagar Madamsetty

Santanu Bhattacharya

Krishnendu Pal

The present invention relates to nimbolide analogs useful as anti-cancer agents and preparation thereof. Particularly the present invention relates to nimbolide analogs of general formula I. wherein, ring M is any ring selected from the group consisting of substituted or unsubstituted aryl, heteroaryl, cycloalkyl and heterocyclic; A and B are selected from the group consisting of C, O, N, S and H; R, R, R, R, Rand Rare selected from the group consisting of C1-C6 alkyl, aryl, heteroaryl, C1-C7 cycloalkyl, heteroalkyl, hydrogen, hydroxy, alkoxy, nitro, halogen, amino, alkylamino, aryl amino and cyano; wherein each of these groups may be further substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, cyano, alkyl amino, aryl amino, alkoxy, amino, nitro, aldehyde, carboxylic acid and ester.

Nimbolide analogs as anti-cancer agents and preparation thereof

The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK(SEQ ID NO: 1)-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK(SEQ ID NO: 1)-lipopeptide, at least two co-lipids, a therapeutic agent, and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering a therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).

Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines

This document provides methods and materials involved in treating cancer. For example, methods and materials involved in making and using particles (e.g., gold nanoparticles) containing a KTLLPTPYC amino acid sequence (SEQ ID NO:1) or a KTLLPTPYCC amino acid sequence (SEQ ID NO:2) to treat cancer (e.g., pancreatic cancer) are provided.

Methods and materials for treating cancer

The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing. There is no visible toxic effect of this composition when injected in mice, indicating that it has minimum to no toxic effect to normal homeostasis. The present invention is likely to find specific application in developing potential therapeutic treatment for aggressive cancers and CSC-like cancers.

Synergistic anti-cancer composition and a process for the preparation thereof

Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.

Peptides and nanoparticles for therapeutic and diagnostic applications

Growing community of inventors

Rochester, MN, United States of America

Debabrata Mukhopadhyay